Sign In
Buy FATE
$2.45
-0.0600 (-2.39%)
At Close: Jul 31, 2026
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 05'th Jan 2026
SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent s
Fate Therapeutics (NASDAQ:FATE) Shares Pass Below Two Hundred Day Moving Average – What’s Next?
05:14am, Wednesday, 24'th Dec 2025
Fate Therapeutics, Inc. (NASDAQ: FATE - Get Free Report) shares crossed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $1.16 and traded as low as
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference
08:00am, Tuesday, 25'th Nov 2025
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a f
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of “Hold” by Brokerages
02:00am, Tuesday, 18'th Nov 2025
Shares of Fate Therapeutics, Inc. (NASDAQ: FATE - Get Free Report) have been assigned a consensus rating of "Hold" from the nine brokerages that are presently covering the firm, Marketbeat.com reports
Robert Bruce's Strategic Moves: AT&T Inc. Sees a -1.41% Portfolio Impact
04:02pm, Thursday, 13'th Nov 2025
Insightful Analysis of Robert Bruce (Trades, Portfolio)'s Third Quarter 2025 13F Filing Robert Bruce (Trades, Portfolio) recently submitted the 13F filing for
Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates
10:41am, Thursday, 13'th Nov 2025
Fate Therapeutics (FATE) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.4 per share a year ago.
Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
08:30am, Thursday, 13'th Nov 2025
Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819, an Off-the-Shelf CD19-targeted CAR T-cell Product Candidate
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Tuesday, 04'th Nov 2025
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent s
Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
11:01am, Tuesday, 04'th Nov 2025
Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Cancer-Focused Stocks Showing Strong Pipeline Progress
12:35pm, Tuesday, 28'th Oct 2025
Relay, Fate and Verastem advance promising cancer therapies, strengthening their pipelines in a rapidly evolving oncology market.
As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythematosus (SLE) were treated with a single dose of FT819 with less-intensive
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of “Hold” by Analysts
01:56am, Friday, 24'th Oct 2025
Shares of Fate Therapeutics, Inc. (NASDAQ: FATE - Get Free Report) have earned a consensus rating of "Hold" from the eight research firms that are covering the company, Marketbeat reports. One researc
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Thursday, 02'nd Oct 2025
SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent s
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Wednesday, 03'rd Sep 2025
SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent
Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates
06:16pm, Tuesday, 12'th Aug 2025
Fate Therapeutics (FATE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.33 per share a year ago.
